Icatibant Fresenius (Icatibant Acetate)

Icatibant acetate is a competitive antagonist of the bradykinin B2 receptor. It binds to this receptor on vascular endothelial cells, preventing bradykinin from causing vasodilation and increased vascular permeability, which are the primary mechanisms behind the swelling seen in HAE attacks.

The dose of Icatibant Fresenius is determined by the prescribing healthcare professional based on the patient’s condition and clinical guidelines. The medication is supplied as a solution for subcutaneous injection, and the prescriber will specify the exact amount and frequency for each individual.

The safety of Icatibant Fresenius in pregnancy and while breastfeeding has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To order Icatibant Fresenius, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling) and any necessary import documentation.

Icatibant is a bradykinin B2 receptor antagonist, whereas other HAE therapies such as C1‑inhibitor concentrates replace the deficient protein. Icatibant directly blocks the downstream mediator bradykinin, offering rapid symptom relief without the need for plasma‑derived products, but the choice of therapy depends on individual patient needs and physician judgment.

Icatibant Fresenius should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and do not freeze or shake the vial. If refrigeration is unavailable for a short period, it may be kept at controlled room temperature (up to 25 °C) for a limited time as specified in the product label.

Icatibant Fresenius is administered as a subcutaneous injection. The prescriber will instruct the patient or caregiver on the injection technique, including site selection (typically the abdomen or thigh), needle size, and any necessary aseptic precautions. The injection is usually given at the onset of an HAE attack.

Serious risks include anaphylaxis, severe hypotension, and unexpected angioedema unrelated to HAE. Patients should be monitored for signs of an allergic reaction, such as difficulty breathing, swelling of the face or throat, or a sudden drop in blood pressure, and seek immediate medical attention if these occur.

Icatibant Fresenius should not be used in individuals with a known hypersensitivity to icatibant acetate or any of the formulation excipients. Caution is also advised for patients receiving ACE inhibitors or ARBs due to the potential for increased bradykinin‑related angioedema. The prescriber will evaluate contraindications on a case‑by‑case basis.